State bans would mean sensitive patient data, such as interactions with a telehealth provider to obtain abortion drugs, could be used against someone as a threat. One expert warned that the value of such data will “skyrocket.”

An Intellia Therapeutics therapy that uses CRISPR to perform in vivo genomic edits has clinical data showing that the therapeutic effects continue for a year in patients. The biotech now plans to speak with regulators about the design for a pivotal clinical trial testing this therapy, a potential one-time treatment for a rare inherited disease.

The decision about whether to allow the procedure now falls to individual state governments, and only 16, plus the District of Columbia, have passed laws to preserve the option, while two others have state constitutional protections that have been cited by state courts as protections for abortion.

The Future of Virtual-First Care eBook, sponsored by Wheel, explores some of the challenges and trends in virtual-first care. It also offers clues as to how healthcare stakeholders envision the future of virtual health.

Medallion — a provider management platform that automates licensing, continuing education tracking, credentialing and compliance — has completed three funding rounds in one year. On Thursday, it closed a $35 million Series C round, which will be used to help the startup attract more hospital and health system customers.

Confidentiality agreements typically prevent the public from obtaining a window into the cases against pharmacy behemoths but a public court filing makes this one different.

Two private equity firms have reached an $890 million deal to buy Radius Health, a company whose main asset is the commercialized osteoporosis drug Tymlos. In other M&A news, cancer biotech F-star Therapeutics is being acquired in a $161 million deal.

Mental health is bucking the overall trend in telehealth utilization. A new report found that telehealth accounted for 87% of mental health appointments booked last month. That percentage is continuing to climb, despite virtual care visits declining across all other specialties.

The Pitch Perfect contest at MedCity INVEST PharmaTech, the free virtual conference scheduled for July 26, will spotlight five startups seeking to improve clinical trials.

Leaders in healthcare draw attention to the myriad ways cloud computing technology is transforming healthcare.

The Clarifying Remanufacturing to Protect Patient Safety Act was introduced by Reps. Scott Peters (D-CA), Kim Schrier (D-WA), and John Joyce (R- PA) to clarify the meaning of medical device remanufacturing and empower the FDA to educate company technicians so they know if they’ve crossed the line into a regulated activity. 

Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, such as sickle cell disease. One of the goals of the alliance is to make genetic medicines more globally accessible.

The speed of Covid-19 vaccine trials should inspire the pharmaceutical and medical device industries to accelerate its clinical testing, according to Shweta Maniar, Google Cloud’s director for healthcare and life sciences. She argued that harnessing real-world data will make faster clinical trials achievable for all therapeutics and devices, possibly even eliminating the need to recruit a placebo arm.

Collecting SDOH, adding this data to patient profiles, enabling health data analytics, and taking data-based actions has proven to help significantly.

The ability of healthcare providers to leverage accurate, sophisticated and timely diagnostic testing for infertility patients is a crucial part of the patient journey.

Providence spun out Advata two weeks ago, and the startup, which has 30 customers and 150 employees, sells a suite of insights-focused data software products designed to improve population health and revenue cycle management.

An Alzheimer’s disease drug from Athira Pharma has failed a Phase 2 clinical trial and the biotech has a surprising theory why. Athira says standard of care drugs Alzheimer’s patients are already taking may diminish the effect of its small molecule and this finding could inform how the company proceeds with an ongoing Phase 3 clinical trial.

A veteran of GE Healthcare, Joe Gasque talks about how he's growing the company's niche position in the high-paced aesthetics industry, offering services to surgeons, practitioners, medical device and injectables manufacturers.

Cardiologs is developing a new model to predict atrial fibrillation. A new study, sponsored by the Paris-based company, showed that the algorithm can accurately predict the near-term presence or absence of AFib using only the first 24 hours of a Holter device recording.

Human Longevity, Inc., a startup founded by genomics pioneer J. Craig Venter, plans to join the public markets via a SPAC merger. If the business combination closes, HLI would receive about $345 million for continued commercialization of its platform that uses genomics, AI, and other technologies for early disease detection and other strategies intended to help people live longer.